Current Status and Future Trends of Cold Atmospheric Plasma as an Oncotherapy

Abstract

Cold atmospheric plasma (CAP), a redox modulation tool, is capable of inhibiting a wide spectrum of cancers and has thus been proposed as an emerging onco-therapy. However, with incremental successes consecutively reported on the anticancer efficacy of CAP, no consensus has been made on the types of tumours sensitive to CAP due to the different intrinsic characteristics of the cells and the heterogeneous design of CAP devices and their parameter configurations. These factors have substantially hindered the clinical use of CAP as an oncotherapy. It is thus imperative to clarify the tumour types responsive to CAP, the experimental models available for CAP-associated investigations, CAP administration strategies and the mechanisms by which CAP exerts its anticancer effects with the aim of identifying important yet less studied areas to accelerate the process of translating CAP into clinical use and fostering the field of plasma oncology.

Cold Atmospheric Plasma: An Emerging Immunomodulatory Therapy

“…The proliferation of deep‐seated cancer cells is still strong, indicating that the effective penetration depth of plasma emission devices is limited, which limits the application of plasma in solid tumors. [ 107 ]…”

Effect of the Cold Atmospheric Plasma Technology for Treatment the Cancer Diseases in the Human: A literature Review

“…According to the research of Attri P. et al 2021, the cold atmospheric plasma has an influence on hematological cancers. According to Dai, et al 2023, plasma is a gas that is only partly ionized and contains…”